Stifel has upgraded its recommendation on Equasens from 'hold' to 'buy', with a target price raised from €66 to €83. The broker also sees potential for the healthcare software company's share price to double over the next five years.

Among the reasons for its upgrade, the broker mentions improved growth and market dynamics, new product launches, European expansion into major markets, first-rate profitability and an attractive valuation.

At the dawn of a change in momentum, with growth set to accelerate in the second half of 2024, we believe there is a great opportunity to invest in a low-risk, high-quality company for the long term", he continues.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.